Stay updated on Pembrolizumab in Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added. The funding-lapse notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding lapse and updated page to Revision: v3.4.1, replacing v3.4.0; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedThe page introduces a glossary toggle and adjusts metadata labels (adding 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0') while removing the prior label 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no changes to study content, eligibility, or results are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page now shows 'Results Submitted' in the results status area, and the previous 'No Results Posted' message has been removed.SummaryDifference0.1%

- Check64 days agoChange DetectedThe Study Details page updated the Locations section, with state locations added and removed, and the page revision updated to v3.3.3.SummaryDifference0.7%

Stay in the know with updates to Pembrolizumab in Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.